Collaborating in care

Collaborate to cure, connect and transform the diagnosis and treatment of serious, complex and rare conditions.

Current therapies for patients with overactive bladder

Overactive bladder and its symptoms can be discouraging and debilitating for patients. Making use of the most current therapies and implementing them in a prescribed sequence, starting with the most conservative measures, is the key to managing the problem.

Newly discovered autoimmune disease associated with testicular cancer

Sean J. Pittock, M.D., an autoimmune neurologist at Mayo Clinic, discusses a newly discovered autoimmune disease that appears to affect men with testicular cancer.

Mayo Clinic in Arizona is improving transplant care for the Hispanic population

The Hispanic Transplant Program at Mayo Clinic in Arizona closes the gap in transplant care and access for patients in the Hispanic population.

Treatment options for advanced kidney cancer

Bradley C. Leibovich, M.D., a urologic surgeon specializing in the treatment of kidney cancer at Mayo Clinic in Rochester, Minnesota, discusses the symptoms that patients with kidney tumors may — or may not — experience, as well as treatment ...

Clinical trial regarding endometrial cancer and stress urinary incontinence

Gynecologic oncologist Gretchen E. Glaser, M.D., with Mayo Clinic in Rochester, Minnesota, discusses a study that compares the quality of life and clinical outcomes among women with endometrial cancer and stress urinary incontinence who ...

A multidisciplinary approach to genitourinary cancers

Mayo Clinic specialists describe considerations and advancements in surgical techniques used in the treatment of testicular cancer, bladder cancer and kidney cancer.

Bladder cancer treatment options

R. Jeffrey Karnes, M.D., consultant and associate professor, Mayo Clinic, discusses treatment options for bladder cancer. The ailment can be subdivided into subcategories, and the treatments dramatically differ. Invasive treatments can ...

Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients

Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors.